Sandbox: sadaf: Difference between revisions

Jump to navigation Jump to search
Ssharfaei (talk | contribs)
Ssharfaei (talk | contribs)
Line 49: Line 49:
|-
|-
! rowspan="23" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Infection
! rowspan="23" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Infection
! align="center" style="background:#DCDCDC;" + |'''Gestational thrombocytopenia'''
! align="center" style="background:#DCDCDC;" + |Gestational thrombocytopenia
!
!
|
|
Line 73: Line 73:
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
|-
|-
!'''Chronic liver disease'''
! align="center" style="background:#DCDCDC;" + |Chronic liver disease
!
!
|
|
Line 97: Line 97:
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
|-
|-
!portal hypertension
! align="center" style="background:#DCDCDC;" + |portal hypertension
!
!
|
|
Line 121: Line 121:
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
|-
|-
!'''Hypersplenism'''
! align="center" style="background:#DCDCDC;" + |Hypersplenism
!
!
|
|
Line 145: Line 145:
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
|-
|-
!'''Immune thrombocytopenia'''
! align="center" style="background:#DCDCDC;" + |Immune thrombocytopenia
!
!
|Antibody-mediated platelet destruction
|Antibody-mediated platelet destruction
Line 169: Line 169:
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
|-
|-
! rowspan="7" |'''Congenital platelet''' '''disorders'''
! rowspan="7" align="center" style="background:#DCDCDC;" + |Congenital platelet disorders
!MYH-9 related disorders
! align="center" style="background:#DCDCDC;" + |MYH-9 related disorders
|
|
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
Line 193: Line 193:
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
|-
|-
!Bernard-Soulier syndrome
! align="center" style="background:#DCDCDC;" + |Bernard-Soulier syndrome
|
|
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
Line 216: Line 216:
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
|-
|-
!Gray platelet syndrome
! align="center" style="background:#DCDCDC;" + |Gray platelet syndrome
|
|
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
Line 239: Line 239:
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
|-
|-
!Wiskott-Aldrich syndrome
! align="center" style="background:#DCDCDC;" + |Wiskott-Aldrich syndrome
|
|
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
Line 262: Line 262:
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
|-
|-
!Thrombocytopenia with absent radius (TAR) syndrome
! align="center" style="background:#DCDCDC;" + |Thrombocytopenia with absent radius (TAR) syndrome
|
|
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
Line 285: Line 285:
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
|-
|-
!Alport syndrome
! align="center" style="background:#DCDCDC;" + |Alport syndrome
|
|
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
Line 308: Line 308:
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
|-
|-
!Von Willebrand disease
! align="center" style="background:#DCDCDC;" + |Von Willebrand disease
|
|
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
Line 427: Line 427:
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
|-
|-
! rowspan="2" align="center" style="background:#DCDCDC;" + |'''Viral infections'''
! rowspan="2" align="center" style="background:#DCDCDC;" + |Viral infections


!rubella, mumps, varicella, parvovirus, hepatitis C, and Epstein-Barr virus
! align="center" style="background:#DCDCDC;" + |rubella, mumps, varicella, parvovirus, hepatitis C, and Epstein-Barr virus
|
|
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
Line 452: Line 452:
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
|-
|-
!'''HIV'''
! align="center" style="background:#DCDCDC;" + |HIV
!
!
* Direct toxicity to megakaryocytes
* Direct toxicity to megakaryocytes
Line 478: Line 478:
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
|-
|-
! rowspan="3" |Bacterial infections
! rowspan="3" align="center" style="background:#DCDCDC;" + |Bacterial infections
!'''Sepsis'''
! align="center" style="background:#DCDCDC;" + |Sepsis
!Direct bone marrow suppression
!Direct bone marrow suppression
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
Line 502: Line 502:
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
|-
|-
!Helicobacter pylori
! align="center" style="background:#DCDCDC;" + |Helicobacter pylori
!Immune thrombocytopenia
!Immune thrombocytopenia
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
Line 525: Line 525:
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
|-
|-
!leptospirosis, brucellosis, anaplasmosis, and other tick-borne infections
! align="center" style="background:#DCDCDC;" + |Leptospirosis, brucellosis, anaplasmosis, and other tick-borne infections
|
|
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
Line 548: Line 548:
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
|-
|-
! rowspan="2" |'''Intracellular parasites'''
! rowspan="2" align="center" style="background:#DCDCDC;" + |Intracellular parasites
!Malaria
! align="center" style="background:#DCDCDC;" + |Malaria
|
|
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
Line 572: Line 572:
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
|-
|-
!Babesiosis  
! align="center" style="background:#DCDCDC;" + |Babesiosis  
|
|
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
Line 596: Line 596:
|-
|-
! rowspan="6" |Medications/toxicity
! rowspan="6" |Medications/toxicity
!'''Drug-induced immune thrombocytopenia'''
! align="center" style="background:#DCDCDC;" + |Drug-induced immune thrombocytopenia
!
!
* Antibiotics  
* Antibiotics  

Revision as of 03:12, 13 August 2018

Thrombocytopenia Differential Diagnosis

Differentiating the diseases that can cause thrombocytopenia:

Category Condition Clinical manifestations Para−clinical findings Gold standard Associated findings
Symptoms Signs
Lab Findings Imaging
Severity Fever Bleeding BP Other CBC PBS Coagulopathy
Mechanism
Infection Gestational thrombocytopenia
Chronic liver disease
portal hypertension
Hypersplenism
Immune thrombocytopenia Antibody-mediated platelet destruction Moderate to severe - Diagnosis of exclusion
Congenital platelet disorders MYH-9 related disorders
Bernard-Soulier syndrome
Gray platelet syndrome
Wiskott-Aldrich syndrome
Thrombocytopenia with absent radius (TAR) syndrome
Alport syndrome
Von Willebrand disease
Viral infections rubella, mumps, varicella, parvovirus, hepatitis C, and Epstein-Barr virus
HIV
  • Direct toxicity to megakaryocytes
  • An ITP-like condition called primary HIV-associated thrombocytopenia (PHAT)
  • Secondary opportunistic infections
Bacterial infections Sepsis Direct bone marrow suppression
Helicobacter pylori Immune thrombocytopenia
Leptospirosis, brucellosis, anaplasmosis, and other tick-borne infections
Intracellular parasites Malaria
Babesiosis
Medications/toxicity Drug-induced immune thrombocytopenia
  • Antibiotics
    • Sulfonamides
    • Ampicillin
    • Piperacillin
    • Vancomycin
    • Rifampin
  • Older antiepileptic agents
    • carbamazepine
    • Phenytoin
  • Quinine
Occurrence of drug-dependent, platelet-reactive antibodies
Heparin-induced thrombocytopenia
Cytotoxic chemotherapy
Radiation therapy Predictable, dose-dependent myelosuppression
OTC agents Quinine-containing beverages
Alcohol
Malignancy
Nutrient deficiencies folate, vitamin B12, copper an autoimmune mechanism Mild
Thrombotic microangiopathy (TMA) Thrombotic thrombocytopenic purpura (TTP)
Hemolytic uremic syndrome (HUS)
Drug-induced TMA (DITMA)
Bone marrow disorders Myelodysplastic syndromes
Aplastic anemia
Acute leukemia
Paroxysmal nocturnal hemoglobinuria (PNH)
Rheumatologic/autoimmune disorders Systemic lupus erythematosus (SLE)
Antiphospholipid syndrome (APS) autoantibody-mediated syndrome
Felty's syndrome splenomegaly
vascular giant capillary hemangioma, platelet destruction
large aortic aneurysms, platelet destruction
cardiopulmonary bypass platelet destruction
Post-transfusion purpura immune-mediated platelet destruction